Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 2 1

Status

Enrolling by invitation 2Completed 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 12INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 931Neoplasms 614Breast Neoplasms 613Colorectal Neoplasms 460Neoplasm Metastasis 399Ovarian Neoplasms 333Prostatic Neoplasms 316Melanoma 316Lung Neoplasms 295Multiple Myeloma 294Recurrence 282Squamous Cell Carcinoma of Head and Neck 248Stomach Neoplasms 233Pancreatic Neoplasms 232Leukemia, Myeloid, Acute 224Triple Negative Breast Neoplasms 194Endometrial Neoplasms 190Carcinoma, Renal Cell 183Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 178Small Cell Lung Carcinoma 166Leukemia, Lymphocytic, Chronic, B-Cell 158Advanced Solid Tumors 158Lymphoma, Follicular 150Lymphoma, Large B-Cell, Diffuse 141Urinary Bladder Neoplasms 140Lymphoma 138Advanced Solid Tumor 137Uterine Cervical Neoplasms 136Head and Neck Neoplasms 134

Interventions

pembrolizumab 1liposomal doxorubicin 1atezolizumab 1Tumor Necrosis Factor-alpha 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Adenoviridae Infections × 1 year × Clear all
NCT07544589 2026-05-29

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

Dispatch Biotherapeutics

Phase 1 Recruiting
66 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenoviridae Infections, Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting
29 enrolled

Adenoviridae Infections

NCT02143804 2026-04-02

exBOND

CG Oncology, Inc.

Phase 2 Withdrawn
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms

NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1/2 Enrolling by invitation
30 enrolled
CNS

Adenoviridae Infections, Glioma

NCT04695327 2026-03-06

TUNIMO

TILT Biotherapeutics Ltd.

Phase 1 Completed
32 enrolled

Adenoviridae Infections

NCT02705196 2026-02-24

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Lokon Pharma AB

Phase 1/2 Completed
51 enrolled
Gastrointestinal

Adenoviridae Infections, Neoplasms, Pancreatic Neoplasms

NCT06215846 2025-11-26

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1 Enrolling by invitation
12 enrolled

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡